Shanghai Aopumai Biotechnology Co., Ltd. (stock abbreviation: Aopumai, stock code: 688293) was established in 2013. It is a high-tech biotechnology enterprise focusing on providing cell culture solutions and end-to-end CDMO services. Oupmai has 4 production bases that meet GMP standards, with a total area of ​​more than 18,000 square meters, and the quality management system has obtained ISO9001:2015 certification (TÜV NORD, Germany). Another new headquarters with a total area of ​​about 30,000 square meters is in the construction stage.

In 2022, Oupmai landed on the Science and Technology Innovation Board and embarked on a new journey. Oupmai will continue to rely on the international advanced technology research and development team and a complete commercial production quality management system, adhere to the quality policy of "highest craftsmanship and best quality", and continue to optimize and innovate. With the core principle of providing diversified, high-performance, highly stable quality products, and with a fast response and continuous service attitude, Oupmai provides excellent, stable and personalized "one-stop" cell culture solutions, becoming a global pharmaceutical manufacturing solution. An important strategic partner of the company.

Oupmai’s medium business provides the world’s leading chemical composition-definition/serum-free cell culture medium products, including shelf-type commercial culture medium, customized culture medium and designated formula commissioned production services. With its excellent product performance, a total of 200+ pharmaceutical R&D pipelines with determined pilot processes use the company's cell culture medium products.

Oupmai CDMO services provide end-to-end overall solutions for the research and development and production of biopharmaceuticals. The CDMO production base complies with the GMP standard and serves every stage of biopharmaceuticals from antibody discovery to commercial production up to 2000L. With its professional service, the company has successfully delivered more than 200 biopharmaceutical development and production projects, and has successfully helped global partners to pass the China-US IND application.